Ten GLP-1 Labels, One Sentence About Gastroparesis — and It Is Not in the Contraindications

If you have gastroparesis and a GLP-1 has come up, you will eventually be handed one sentence out of the prescribing information. It is worth knowing exactly what that sentence says, where in the document it sits, and what it does not say — because all three change what it means for you.

The sentence is the same on every label

Ten FDA labels cover this class: four molecules, three manufacturers, ten brand names. They carry the same instruction, worded almost identically.

Ozempic, label revised June 2026: "Use has been associated with gastrointestinal adverse reactions, sometimes severe. OZEMPIC is not recommended in patients with severe gastroparesis. ( 5.7 )"

Zepbound, revised May 2026: "ZEPBOUND is not recommended in patients with severe gastroparesis. ( 5.2 )"

Wegovy, revised June 2026: "WEGOVY is not recommended in patients with severe gastroparesis. ( 5.6 )"

Byetta, revised September 2025: "BYETTA is not recommended in patients with severe gastroparesis. ( 5.5 )"

That level of agreement is unusual. On most questions these labels diverge — kidney thresholds, retinopathy figures, gallbladder rates all differ by brand. Here they converge, and they converge on wording that was written independently for each product.

It is not a contraindication, and the labels are careful about that

A prescribing document keeps two separate registers. Section 4, Contraindications, lists the conditions under which the drug is not to be used. Section 5, Warnings and Precautions, holds risks to weigh, monitor and discuss.

Gastroparesis appears in Section 5 on all ten labels. It appears in Section 4 on none of them.

What Section 4 does contain, in Ozempic's case: "OZEMPIC is contraindicated in patients with: • A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )] . • A serious hypersensitivity reaction to semaglutide"

Thyroid C-cell tumour history and hypersensitivity. That is the whole list. A history of severe gastroparesis is not on it, on any label in the class.

This distinction is not a technicality. "Not recommended" is an instruction to the prescriber to have a reason; "contraindicated" is an instruction to stop. Articles that describe gastroparesis as a contraindication for GLP-1s are describing a document that does not exist.

The operative word is "severe", and nothing defines it

Every one of those sentences qualifies the condition. Not gastroparesis — severe gastroparesis.

No label in the class defines the threshold. There is no gastric-emptying percentage, no scintigraphy cutoff, no symptom score. The labels also say nothing at all about mild or moderate delayed emptying, which is the situation far more people are actually in.

Silence is not permission. But it is silence, and it is worth knowing that the sentence you will be quoted was written about severe disease, and that the line between severe and moderate is left entirely to the people in the room.

One manufacturer hedges the first half

Nine of the ten labels open the warning the same way: use "has been associated" with gastrointestinal adverse reactions.

Trulicity, revised August 2026, does not: "Use may be associated with gastrointestinal adverse reactions, sometimes severe. TRULICITY is not recommended in patients with severe gastroparesis ( 5.6 )."

Has been, against may be. The second half of Lilly's sentence matches everyone else exactly; only the causal claim is softened. It is a small difference and it is a real one — the same company writes "has been associated" on its own Mounjaro and Zepbound labels.

Placement is per-drug, not copy-paste

The warning carries a different section number on nearly every label — ( 5.2 ) on Zepbound, ( 5.5 ) on Byetta, ( 5.6 ) on Trulicity and Wegovy, ( 5.7 ) on Ozempic. Each label orders its own warnings by that product's risk profile, then numbers them.

The contraindications behave the same way. Byetta's Section 4 has no thyroid entry at all: "BYETTA is contraindicated in patients with: • A prior severe hypersensitivity reaction to exenatide or to any of the excipients in BYETTA."

Exenatide carries no medullary thyroid carcinoma contraindication, while semaglutide, liraglutide, tirzepatide and dulaglutide all do. So Section 4 really is written per molecule — which is what makes the absence of gastroparesis from all ten of them meaningful rather than accidental.

Why the class touches this at all

These drugs slow gastric emptying. That is not a side effect the manufacturers are working around; it is part of how the drugs produce fullness, and each label describes it in Clinical Pharmacology. Gastroparesis is delayed gastric emptying as a disease. The concern is that the two stack.

That mechanism is the standard pharmacological explanation rather than a finding quoted from any single trial, and it is offered here as such.

Where the mechanism has a documented consequence

The same delayed emptying drives a separate warning that FDA added across the class, and that one is worth reading alongside this. From Wegovy's Section 5.10: "There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations."

Residual stomach contents in people who did fast. If you have gastroparesis and any procedure requiring sedation is planned, that paragraph is the one to bring, and our page on GLP-1s and surgery goes through what the label does and does not tell your anaesthetist to do about it.

What this adds up to

The labels give a prescriber a reason to hesitate and nothing that forbids. They set no threshold, define no severity scale, and leave moderate delayed emptying unaddressed. That means the decision genuinely sits with you and your clinician rather than with the document — and it means anyone who tells you the label rules it out has not read Section 4.

Bring the actual sentence to the appointment. It is short, it is specific about severity, and it is in Warnings and Precautions.

This page quotes FDA-approved labelling and is educational information, not medical advice. Gastroparesis severity is a clinical judgement no article can make for you.